TBH score: a new model to predict and prevent severe liver damage after chemotherapy for cancer patients

References

• Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 1995;333(17):1118–1127. doi:10.1056/NEJM1995102633317067565951
   PubMed Web of Science ®Google Scholar
• Ishak KG, Zimmerman HJ. Morphologic spectrum of drug-induced hepatic disease. Gastroenterol Clin North Am. 1995;24(4):759–786.8749898
   PubMed Web of Science ®Google Scholar
• Chun YS, Laurent A, Maru D, Vauthey JN. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol. 2009;10(3):278–286. doi:10.1016/S1470-2045(09)70064-619261256
   PubMed Web of Science ®Google Scholar
• Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol. 2000;64(5):281–291.10863974
   PubMed Web of Science ®Google Scholar
• Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant. 2008;41(3):229–237. doi:10.1038/sj.bmt.170589917994121
   PubMed Web of Science ®Google Scholar
• Brouquet A, Benoist S, Julie C, et al. Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. Surgery. 2009;145(4):362–371. doi:10.1016/j.surg.2008.12.00219303984
   PubMed Web of Science ®Google Scholar
• Sorensen P, Edal AL, Madsen EL, Fenger C, Poulsen MR, Petersen OF. Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil. Cancer. 1995;75(10):2592–2596.7736406
   PubMed Web of Science ®Google Scholar
• Dyson JK, McPherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J Clin Pathol. 2013;66(12):1033–1045. doi:10.1136/jclinpath-2013-20162023940130
   PubMed Web of Science ®Google Scholar
• van der Bol JM, Mathijssen RH, Loos WJ, et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol. 2007;25(19):2719–2726. doi:10.1200/JCO.2006.09.611517563393
   PubMed Web of Science ®Google Scholar
• Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247(1):118–124. doi:10.1097/SLA.0b013e31815774de18156931
   PubMed Web of Science ®Google Scholar
• Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5(3):224–237.10884501
   PubMedGoogle Scholar
• Chitturi S, Farrell GC. Drug-induced liver disease. Curr Treat Options Gastroenterol. 2000;3(6):457–462.11096606
   PubMedGoogle Scholar
• Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–181. doi:10.1016/S1053-4296(03)00031-612903007
   PubMed Web of Science ®Google Scholar
• Makowiec F, Mohrle S, Neeff H, et al.. Chemotherapy, liver injury, and postoperative complications in colorectal liver metastases. J Gastrointest Surg. 2011;15(1):153–164. doi:10.1007/s11605-010-1368-721061183
   PubMed Web of Science ®Google Scholar
• Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24(13):2065–2072. doi:10.1200/JCO.2005.05.307416648507
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg. 2007;11(7):860–868. doi:10.1007/s11605-007-0149-417492335
   PubMed Web of Science ®Google Scholar
• Abangah G, Yousefi A, Asadollahi R, Veisani Y, Rahimifar P, Alizadeh S. Correlation of body mass index and serum parameters with ultrasonographic grade of fatty change in non-alcoholic fatty liver disease. Iran Red Crescent Med J. 2014;16(1):e12669. doi:10.5812/ircmj.1266924719704
   PubMed Web of Science ®Google Scholar
• Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study. Hepatology. 2005;42(1):44–52. doi:10.1002/hep.2073415895401
   PubMed Web of Science ®Google Scholar
• Donati G, Stagni B, Piscaglia F, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut. 2004;53(7):1020–1023. doi:10.1136/gut.2003.02708615194655
   PubMed Web of Science ®Google Scholar
• Ikuta T, Kanno K, Arihiro K, et al. Spontaneously hypertensive rats develop pronounced hepatic steatosis induced by choline-deficient diet: evidence for hypertension as a potential enhancer in non-alcoholic steatohepatitis. Hepatol Res. 2012;42(3):310–320. doi:10.1111/j.1872-034X.2011.00920.x22176027
   PubMed Web of Science ®Google Scholar
• Hsu CT. Ultrastructural changes in liver damage induced by carbon tetrachloride in spontaneously hypertensive rats and Wistar-Kyoto rats. J Auton Nerv Syst. 1998;70(1–2):79–83.9686907
   PubMedGoogle Scholar
• Arima S, Uto H, Ibusuki R, et al. Hypertension exacerbates liver injury and hepatic fibrosis induced by a choline-deficient L-amino acid-defined diet in rats. Int J Mol Med. 2014;33(1):68–76. doi:10.3892/ijmm.2013.154424190226
   PubMed Web of Science ®Google Scholar
• Li XP, Wen F, Yang W, et al. The role of tiopronin for the prevention of chemotherapy-related liver toxicity in advanced colorectal cancer patients treated with mFOLFOX7: a prospective analysis. Tumori. 2014;100(4):446–451. doi:10.1700/1636.1790825296595
   PubMed Web of Science ®Google Scholar
• Yan Y, Mo Y, Zhang D. [Magnesium isoglycyrrhizinate prevention of chemotherapy-induced liver damage during initial treatment of patients with gastrointestinal tumors]. Zhonghua Gan Zang Bing Za Zhi. 2015;23(3):204–208. doi:10.3760/cma.j.issn.1007-3418.2015.03.01025938834
   PubMedGoogle Scholar
• Santini D, Vincenzi B, Massacesi C, et al. (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. Anticancer Res. 2003;23(6d):5173–5179.14981985
   PubMed Web of Science ®Google Scholar
• Rubbia-Brandt L, Lauwers GY, Wang H, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010;56(4):430–439. doi:10.1111/j.1365-2559.2010.03511.x20459550
   PubMed Web of Science ®Google Scholar
• van der Pool AE, Marsman HA, Verheij J, et al. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases. J Surg Oncol. 2012;106(7):892–897. doi:10.1002/jso.2314222552819
   PubMed Web of Science ®Google Scholar